NUVB: Nuvation Bio - Update #5

A purely technical post regarding Nuvation Bio (NUVB). Technical analysis is the practice of using historical data and current price action, to predict future price movements. Since March of 2024 the stock has hit the $4.00 ceiling level and has turned back down on three occasions. It could be investors taking profits, or short sellers looking for opportunity at that level. NUVB finally broke out higher of that level this week, bringing in new technical strength of higher prices to the stock, chart below. The company will report third quarter earning's on November 3rd, when we'll get the fundamental investment details. 

 

NUVB: Nuvation Bio - Update #3

An update on Nuvaton Bio's progress the past few months, as the company and stock have been performing well since receiving FDA approval of Taletrectinib, a drug for ROS1-positive non small cell lung cancer (NSCLC). Another drug in their pipeline NUV-1511 is in clinical studies for five indications. 

 Financial Statistics: 

• $608 million cash
• Debt - minimal
• 341 million diluted shares outstanding
• 938 million market cap

Intellectual Property:

• Taletrectinib - Expected to expire from 2033 to 2042
• Safusidenib - Expected to expire from 2035 to 2041
• NUV-1511 - Expected to expire 2039 to 2043

Nuvation Bio's pipeline includes NUV-1511 a drug known as a DCC (drug-drug conjugate), which is in a phase 1/2 being tested for patients with advanced solid tumors in five separate indications here NUV-1511. This large study will include 466 patients to conclude in early 2027. The company expects more details forthcoming. Weekly chart below of Nuvation, thank you for reading.